We are live on ! Find out more
KALA icon

KALA BIO

64 hedge funds and large institutions have $112M invested in KALA BIO in 2018 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 24 increasing their positions, 9 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

827% more call options, than puts

Call options by funds: $510K | Put options by funds: $55K

167% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 9

100% more funds holding in top 10

Funds holding in top 10: 24 (+2)

50% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 10

8% more funds holding

Funds holding: 5964 (+5)

0% more ownership

Funds ownership: 0.03%0.03% (+0%)

29% less capital invested

Capital invested by funds: $159M → $112M (-$46.2M)

Holders
64
Holders Change
+5
Holders Change %
+8.47%
% of All Funds
1.43%
Holding in Top 10
4
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+100%
% of All Funds
0.09%
New
15
Increased
24
Reduced
9
Closed
10
Calls
$510K
Puts
$55K
Net Calls
+$455K
Net Calls Change
-$19K
Name Holding Trade Value Shares
Change
Change in
Stake
RCM
1
RA Capital Management
Massachusetts
$22.2M +$16.8M +971 +115%
O
2
OrbiMed
New York
$16.9M
PVMCV
3
Polaris Venture Management Co V
Massachusetts
$9.08M
Wellington Management Group
4
Wellington Management Group
Massachusetts
$7.46M -$399K -23 -4%
BlackRock
5
BlackRock
New York
$6.98M +$2.24M +129 +29%
CC
6
Caxton Corporation
New Jersey
$6.64M +$9.07M +523 +2,490%
ACM
7
Athyrium Capital Management
New York
$6.52M +$9.26M +534 New
VC
8
Vivo Capital
California
$5.1M
Vanguard Group
9
Vanguard Group
Pennsylvania
$4.96M +$3.5M +202 +99%
SI
10
Sofinnova Investments
California
$2.18M +$2.43M +140 +368%
BC
11
Broadfin Capital
New York
$1.66M -$52K -3 -2%
T. Rowe Price Associates
12
T. Rowe Price Associates
Maryland
$1.46M -$797K -46 -28%
Renaissance Technologies
13
Renaissance Technologies
New York
$1.42M +$1.72M +99 +550%
Deutsche Bank
14
Deutsche Bank
Germany
$1.31M +$1.39M +80 +296%
JP Morgan Chase
15
JP Morgan Chase
New York
$1.25M +$676K +39 +61%
Dimensional Fund Advisors
16
Dimensional Fund Advisors
Texas
$1.25M +$676K +39 +62%
FI
17
Fosun International
China
$1.21M +$1.72M +99 New
PVI
18
Pura Vida Investments
New York
$1.06M +$1.49M +86 New
Brown Advisory
19
Brown Advisory
Maryland
$1.03M
State Street
20
State Street
Massachusetts
$993K +$52K +3 +4%
Geode Capital Management
21
Geode Capital Management
Massachusetts
$977K +$607K +35 +78%
GX
22
Greylock XII
California
$976K
Northern Trust
23
Northern Trust
Illinois
$925K +$416K +24 +46%
OAM
24
Oxford Asset Management
United Kingdom
$849K +$1.14M +66 +1,650%
Millennium Management
25
Millennium Management
New York
$787K -$1.61M -93 -59%

KALA Hedge Fund Activity: Q4 2018 in Review

64 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in KALA BIO (KALA) for Q4 2018, worth a combined $112M — down 29% from $159M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new KALA positions and 10 closed out — a net gain of 5 holders — while 24 added to existing stakes and 9 trimmed.

The largest buyer was RA Capital Management, adding an estimated $16.8M. The largest seller was Fidelity Investments, exiting entirely with an estimated $3.13M sold.

  • 64 institutional investors held KALA BIO (KALA) as of Q4 2018, up from 59 in Q3 2018.
  • Funds reported $112M of KALA BIO stock for Q4 2018, down 29% quarter-over-quarter.
  • 15 funds opened new KALA BIO positions in Q4 2018 and 10 closed out, a net change of +5 holders.
  • The largest KALA BIO buyer in Q4 2018 was RA Capital Management, an estimated $16.8M added.
  • The largest KALA BIO seller in Q4 2018 was Fidelity Investments, an estimated $3.13M sold.

Based on aggregated 13F filings for Q4 2018.